1,1-di(3'-furyl)ethylene | 161227-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 1,1-di(3'-furyl)ethylene
• 英文别名: 1,1-di-3-furylethylene；1,1-di(furan-3-yl)ethylene；1,1-di(3-furyl).ethylene；1,1-di(3-furyl)ethylene；3-[1-(furan-3-yl)ethenyl]furan
• CAS: 161227-86-7
• 化学式: C₁₀H₈O₂
• 分子量: 160.172
• InChiKey: DCCZJDHJBZQVGK-UHFFFAOYSA-N

物化性质

• 沸点：
  220.9±20.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-di(3'-furyl)ethylene 、 1-butylimidazo[1,2-b]isoquinolin-4-ium hexafluorophosphate 在 Dowex 1*2-200(Cl^-) 作用下， 以 乙腈 为溶剂， 以52%的产率得到11,11-di-3-furyl-5,10-ethano-5,10-dihydro-1-butylimidazol<1,2-b>isoquinolin-4-ium chloride
  参考文献：
  名称：

  Novel NMDA Antagonists: Replacement of the Pyridinium Ring of 6,11-Ethanobenzo[b]quinolizinium Cations with Heteroisoquinolinium Cations

  摘要：

  Replacement of the pyridinium ring of 6,11-ethanobenzo[b]quinolizinium cations with thiazolium (4a and 4b) and N-methylimidazolium (4c and 4d) resulted in equipotent compounds in the [H-3]TCP binding assay. The corresponding N-methyl-1,2,4-triazolium analogs were less potent in this assay. The thiazolium derivative 4b, with a K-i = 2.9 nM, is being evaluated as a possible neuroprotective N-methyl-D-aspartic acid (NMDA) antagonist.

  DOI：

  10.1021/jm00010a028
• 作为产物：
  描述：

  bis(furan-3-yl) ketone 、 亚甲基三苯基膦烷 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 1,1-di(3'-furyl)ethylene
  参考文献：
  名称：

  Discovery of 6,11-Ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium Cations, a Novel Class of N-Methyl-D-aspartate Antagonists

  摘要：

  6,11-Ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations 8, a novel class of N-methyl-D-aspartate (NMDA) antagonists acting at the phencyclidine site, have been identified. Structure-activity relationship studies around the lead compound 8a led to the identification of 12g (WIN 67870-2), one of the most potent compounds in this series. Compound 12g has a K-i = 1.8 +/- 0.2 nM vs [H-3]TCP binding, has 700-fold selectivity for binding to the open state of the NMDA receptor-ionophore, and was devoid of MK-801- and PCP-like behavioral effects in rats. Compound 12g was neuroprotective in cultured mouse cortical neurons and exhibited antiischemic activity in a rat middle cerebral artery occlusion/reperfusion model of focal ischemia.

  DOI：

  10.1021/jm00001a006
• 作为试剂：
  描述：

  正丁基锂 、 正己烷 、 、 氯化铵 、 Dme thf dmpu 在 甲基三苯基溴化膦 水 、 silica 、 正己烷 、 hexane-diethyl ether 、 1,1-di(3'-furyl)ethylene 作用下， 以 乙醚 、 水 为溶剂， 反应 2.17h， 以10% ether/hexane) to afford 51 g (86%) of 1,1-di(3-furyl)ethylene (Formula III: R2 =R3 =H;R4 =R5 =3-furanyl)的产率得到1,1-di(3'-furyl)ethylene
  参考文献：
  名称：

  Substituted heterocyclylisoquinolinium salts and compositions and method

  摘要：

  替代杂环异喹啉盐，含有它们的药物组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。

  公开号：

  US05569655A1

文献信息

• Substituted heterocyclylisoquinolinium salts and compositions and
  申请人：Sterling Winthrop Inc.

  公开号：US05604224A1

  公开（公告）日：1997-02-18

  Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  替代杂环异喹啉盐，含有它们的制药组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Substituted 6,11-ethano-6,11-dihydrobenzo[B]quinolizinium salts and
  申请人：Sanofi Winthrop, Inc.

  公开号：US05631264A1

  公开（公告）日：1997-05-20

  Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  该专利描述了6,11-乙烷基-6,11-二氢苯并[b]喹啉盐的替代物，含有它们的制药组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof
  申请人：STERLING WINTHROP INC.

  公开号：EP0656359A1

  公开（公告）日：1995-06-07

  Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts of Formula, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  式中的取代的 6,11-乙hano-6,11-二氢苯并[b]喹嗪盐、 含有它们的药物组合物，以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof
  申请人：STERLING WINTHROP INC.

  公开号：EP0647641A1

  公开（公告）日：1995-04-12

  Substitutued heterocyclylisoquinolinium salts of Formula pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  式的取代杂环异喹啉盐 含有它们的药物组合物，以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Novel Benzo[b]quinolizinium Cations as Uncompetitive N-Methyl-D-aspartic Acid (NMDA) Antagonists: The Relationship between log D and Agonist Independent (Closed) NMDA Channel Block
  作者：William G. Earley、Virendra Kumar、John P. Mallamo、Chakrapani Subramanyam、John A. Dority、Matthew S. Miller、Diane L. DeHaven-Hudkins、Lisa D. Aimone、Michael D. Kelly、Brian Ault

  DOI：10.1021/jm00018a018

  日期：1995.9

  A series of permanently charged benzo[b]quinolizinium cations having lower lipophilicity than MK-801 or phencyclidine (PCP) were synthesized. Data relating agonist independent block of N-methyl-D-aspartic acid (NMDA) ion channels to log D are described.; Closed channel access is predicted to result in a more noncompetitive profile of antagonism compared to selective open channel blockers, which are uncompetitive inhibitors. Reduced closed channel block may underlie the absence of PCP or MK-801-like behavioral side effects observed for benzo[b]quinolizinium cations.